VistaGen Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $12.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors related to VistaGen Therapeutics’ ongoing clinical trials and financial outlook. The company is progressing with its Phase 3 PALISADE-3 and PALISADE-4 studies for fasedienol in social anxiety disorder, with key data readouts expected by the end of 2025 and the first half of 2026, respectively. The successful outcome of these trials, particularly following the positive results from the previous PALISADE-2 study, could position VistaGen for a New Drug Application submission, enhancing the company’s prospects.
Additionally, VistaGen’s financial position appears stable, with $77.2 million in cash expected to support operations through mid-2026, covering the period for the top-line results from both ongoing studies. The valuation model anticipates the commercialization of fasedienol by FY28, with a calculated 12-month price target of $12, factoring in revenue risk adjustments and a 25% discount rate. These elements collectively contribute to the Buy rating, reflecting confidence in the company’s potential for growth and successful drug development.